StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
QZG.SI$0.06+0.00%
Fair $0.06+0.0%

QZG.SI

Accrelist Ltd.

Healthcare / Medical Care FacilitiesSES

$0.06

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $0.06Fund rank 26/100 · Data gapFallback financials|
SA 28/D
F-Score: 3/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 18%

FCF escenarios

weak_data · normalized FCF $-3.2M · quality 44.7/100

Data gap 26/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 15/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

28/100

D

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -49.9%, below the 5% threshold
Thesis & Journal · QZG.SILocal privado en este navegador · Accrelist Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$18M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-49.9%

↓

Gross Margin

38.1%

↓

Debt/Equity

0.43

↑
52-Week Range$0
$0$0

TradingView lightweight chart

QZG.SI price, volumen y niveles de valoración

Último $0.055Periodo -99.7%
Fair value: $0.055

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-29.8%

FCF CAGR

—

FCF margin

-22.9%

FCF / Net income

0.69x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $14.0M · net income $-4.7M · FCF $-3.2M

2022-FY → 2025-FY

Gross margin

38.1%+21.6% pts

Operating margin

-40.3%-28.3% pts

Net margin

-33.2%-4.1% pts

FCF margin

-22.9%-17.7% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$14.0M$14.0M$13.4M$19.1M$40.6M
Net Income$-4.7M$-4.7M$-2.3M$-5.4M$-11.8M
EBITDA$-4.8M$-4.8M$-3.1M$2.1M$-6.1M
EPS-0.01-0.01-0.01-0.02-0.04
Gross Margin38.1%38.1%32.4%28.2%16.5%
Operating Margin-40.3%-40.3%-42.4%-22.6%-12.0%
Net Margin-33.2%-33.2%-17.4%-28.2%-29.1%
Balance Sheet
Debt/Equity0.430.430.260.410.70
Current Ratio1.081.08———
Cash Flow
Free Cash Flow$-3.2M$-3.2M$-8.3M$423000.00$-2.1M
Returns
ROE-49.9%-49.9%-17.9%-34.1%-57.6%
Valuation
EV/EBITDA———4.75—
P/B1.861.861.221.190.70
Growth & Yield
Revenue Growth5.0%5.0%-30.1%-52.9%—
EPS Growth-96.0%-96.0%57.9%55.8%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +61.8%

Total return

+61.8%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.01 → -0.01

Residual

+61.8%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+61.8%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.